SH PHARMA News

Research report to seize opportunities | Orient Securities: sh pharma's revenue maintains steady growth, initiating a "buy" rating.

Gelonghui FinanceNov 18 16:47

Shanghai Pharmaceutical (601607): Leading innovation, reform and revitalization in industrial and commercial integration

orient securitiesNov 18 14:47

Citigroup: Maintains a "buy" rating on Sh Pharma (02607) with a target price lowered to 15.3 Hong Kong dollars

Zhitong FinanceNov 12 11:16

Major rating | Citigroup: Downgrade Shanghai Pharmaceuticals' target price to HK$15.3, maintain a "buy" rating.

Gelonghui FinanceNov 12 11:05

Shanghai Pharmaceutical (601607) 2024 Q3 Report Review: Steady Business Growth in Q3, Improved Industrial Profitability

Huafu SecuritiesNov 8 15:22

Soochow Securities: First buy rating given to Sh Pharma, commercial sector expected to maintain double-digit growth.

Gelonghui FinanceNov 7 15:51

Shanghai Pharmaceutical (601607): Pharmaceutical CSO enables rapid commercial growth, and the industrial sector continues to promote research and development of new drugs

soochow securitiesNov 7 07:47

Goldman Sachs: Downgrade sh pharma's target price to HKD 12.87, lowering earnings forecast reflects lower gross margin in the third quarter.

Gelonghui FinanceNov 5 16:38

Large-scale rating | Lyon: Raised sh pharma's target price to HK$13.8, rated "outperform".

Gelonghui FinanceNov 4 13:32

Shanghai Pharmaceutical (601607): Steady increase in Q3 revenue side, industrial and commercial innovation continues to advance

Guotou SecuritiesNov 1 07:42

Shanghai Pharmaceutical (601607): CSO increased 176% year over year to build an open source innovation ecosystem

sinolinkOct 29 00:00

Research reports Mining | Xiangcai Securities: sh pharma's overall net margin remains stable, first issued a "shareholding" rating

Gelonghui FinanceOct 18 15:25

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17 09:53

Shanghai Pharmaceutical (601607): Industrial-commercial integration leader actively develops innovative businesses

Xiangcai SecuritiesOct 17 07:46

Shanghai Pharmaceutical (601607): Marketing reforms optimize profitability, innovate business and accelerate growth

Sep 10 18:36

Shanghai Pharmaceutical (2607.HK) 2024 Interim Report Review: Performance is in line with expectations; CSO business growth rate is remarkable

Sep 2 00:00

Bank of America Securities: Reiterates 'buy' rating on Sh Pharma (02607), target price reduced to HK$13.7.

Zhitong FinanceAug 28 16:09

Major rating|DBS: Upgrades sh pharma's target price to 18.4 Hong Kong dollars, reiterates "shareholding" rating.

Gelonghui FinanceAug 28 10:47

Shanghai Pharmaceutical (601607): Contrary to the trend of growth, innovation and implementation

Aug 28 00:00

Shanghai Pharmaceutical (601607): Performance is in line with expectations, and the CSO business maintains a rapid growth trend

Aug 27 10:56